What we do
We have developed a unique portal of humanized monoclonal antibodies as a subcutaneous treatment for rare diseases. Such rare diseases require attention as each patient deserves world class treatment. The humanized monoclonal antibodies are specific to the Complement Alternative Pathway (CAP) which plays an important role in the disease. Classical Pathway remains fully functional for the control of the immune system. Unlike other drugs that are under development, our humanized monoclonal antibodies present state-of-the-art for treating rare forms of chronic diseases. learn more
For treating complement-mediated diseases, the drug must be; selective for the CAP and must prevent formation and deposition of C3b and C5b-9, Our humanized monoclonal antibodies possess both such activities. Our humanized monoclonal antibodies bind the target proteins with picomolar affinity and selectively block the CAP by blocking the formation and deposition of C3b and C5b-9. Such properties are desirable in developing highly effective therapeutics for various rare diseases.
We have generated significant in vitro and in vivo pre-clinical and toxicological data which enabled us to file for an IND with the US FDA. Drug manufacturing process has been established and will be used to generate material for human clinical trial in 2018. We have created an exciting pipeline of therapeutic candidates especially for orphan diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH), C3-Glomerulopathy (C3G), and Neuromyelitis Optica (NMO). We believe that our portfolio of therapeutic antibodies has the potential for a better safety and efficacy profile than currently marketed drugs and those that are under development.